CD4 and mature T-cell and NK-cell non-Hodgkin lymphoma: Following treatment with LY249002, a pan-PI3K inhibitor, primary canine CD4+ PTCL cells harvested from patient lymph nodes exhibited significantly increased total cell death compared to DMSO-treated controls (p-value = 0.0078) (Fig. 4C, D).